Synthroid Shortage: What Providers and Prescribers Need to Know in 2026

Levothyroxine (Synthroid) is among the three most prescribed medications in the United States. When supply disruptions occur — even localized or temporary ones — the volume of affected patients creates a significant clinical management burden for prescribers. This guide summarizes the 2026 availability landscape, evidence-based switching protocols, and practical guidance for managing patients during periods of limited Synthroid access.

Current Availability Status (2026)

As of early 2026, oral levothyroxine tablets (including Synthroid brand) are not listed on the FDA's official drug shortage database. However:

In March 2025, Kaiser Permanente issued a formal patient notification of a "critical reduction in supply" of levothyroxine tablets.

The ASHP drug shortage database continues to list levothyroxine sodium injection as in shortage (hospital IV use only; does not affect oral tablets).

Patients report ongoing localized difficulty finding specific strengths (88 mcg, 137 mcg, 175 mcg, 300 mcg) at large retail chain pharmacies.

Multiple levothyroxine manufacturers (Mylan, Northstar, Macleods, AbbVie) maintain separate supply chains, meaning pharmacy-level stocking varies by wholesaler relationships.

Brand vs. Generic: What Prescribers Need to Know

The FDA has determined that certain generic levothyroxine products are therapeutically equivalent to Synthroid. However, levothyroxine has a narrow therapeutic index (NTI), which means formulation differences can produce clinically significant TSH changes in some patients — even at the same microgram dose.

Key clinical guidance:

The American Thyroid Association (ATA) and American Association of Clinical Endocrinologists (AACE) recommend that patients remain on the same levothyroxine formulation once stabilized.

Any switch between Synthroid brand, generics, or other branded levothyroxines should be followed by TSH monitoring at 6–8 weeks.

Not all generic manufacturers are therapeutically equivalent to each other — the FDA equivalence determination applies to brand-to-generic comparison, not cross-generic substitution.

For patients with absorption concerns (GI conditions, PPI use, post-bariatric surgery), Tirosint gel capsules may offer more consistent bioavailability.

Switching Protocols When Synthroid Is Unavailable

When a patient cannot obtain their usual Synthroid formulation, the following protocol is recommended:

Identify the alternative: Consider generic levothyroxine (multiple manufacturers), Levoxyl, Euthyrox, Unithroid, or Tirosint. For patients requiring T3 as well, liothyronine (Cytomel) in combination with levothyroxine is an option.

Use 1:1 microgram conversion: Switch to the same microgram dose (e.g., Synthroid 100 mcg → generic levothyroxine 100 mcg). There is no dose adjustment needed for brand-to-generic switches in most patients.

Counsel the patient: Inform them of the switch, advise them to watch for hypo- or hyperthyroid symptoms, and set a TSH recheck appointment for 6–8 weeks.

Document the switch: Note the reason (supply availability), the specific manufacturer/brand switched to, and TSH monitoring plan.

Levothyroxine Drug Interactions Clinicians Must Manage

When switching formulations, absorption interactions become especially relevant since the new product's excipients may change GI absorption kinetics. Key interactions affecting levothyroxine absorption:

Calcium carbonate and iron supplements — bind levothyroxine in the gut; separate by 4 hours

Proton pump inhibitors (PPIs) — reduce levothyroxine absorption; nearly 70% of interacting drugs in one major study were PPIs; avoid concurrent use when possible

Cholestyramine, colesevelam, sevelamer — bind levothyroxine; separate by at least 4 hours

Carbamazepine, phenytoin, rifampin — increase hepatic metabolism of levothyroxine; may require dose increase

Warfarin — levothyroxine potentiates anticoagulant effect; INR monitoring essential during any dosage adjustment

Special Populations: Pregnancy, Elderly, Cardiac Disease

Pregnancy: TSH requirements increase during pregnancy; do not discontinue levothyroxine. TSH should be monitored every 4 weeks during the first half of pregnancy, and at least once between 26–32 weeks. Return to pre-pregnancy dosing immediately after delivery and recheck TSH at 6–8 weeks postpartum.

Elderly and cardiac patients: Initiate at lower doses (25 mcg/day) and titrate slowly. Overtreatment risk includes atrial fibrillation — the most common arrhythmia associated with levothyroxine excess in elderly patients. Monitor EKG if clinically indicated during formulation switches.

How to Help Patients Find Synthroid When Stock Is Limited

Direct patients to medfinder for providers. medfinder calls pharmacies near the patient to identify which have their specific medication and strength in stock, then texts the results. This reduces the back-and-forth burden on your staff and ensures patients aren't going without their medication while calling pharmacies themselves.

Additional provider tools:

FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — monitor for official shortage listings

ASHP Drug Shortage Resource Center: ashp.org/drug-shortages — often flags issues before FDA

Synthroid Delivers Program (AbbVie): Direct mail-order at $39.95/month for cash-pay patients who prefer brand

For a comprehensive step-by-step approach to helping patients locate their medication, see our provider's guide to helping patients find Synthroid.